Products
Norgestimate is commercially available in tablet form in combination with ethinyl estradiol (Cilest). It has been approved in many countries since 1986.
Structure and properties
Norgestimate (C23H31NO3, Mr = 369.5 g/mol) is a prodrug that is biotransformed in the body to the active metabolites norgestrel and norelgestromin (17-deacetyl norgestimate).
Effects
The combination (ATC G03AA11) is reliably contraceptive (Pearl index < 1). Effects are due to inhibition of ovulation, alteration of cervical mucus and endometrium.
Indications
In combination with ethinyl estradiol for oral hormonal contraception.
Dosage
According to the SmPC. Tablets are taken at the same time each day for 21 consecutive days, followed by a one-week break from taking the tablets, during which bleeding usually begins.
